Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase III Treatment Active 18 and over Pharmaceutical / Industry A6181114
NCT00428220

Trial Description

Summary

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181107, A6181108, A6181110, A6181111, or A6181112.

Eligibility Criteria

Inclusion Criteria:

Must have ended treatment from one of the following sunitinib studies: A6181107, A6181108, A6181110, A6181111, or A6181112.

Exclusion Criteria:

See inclusion criteria

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Pfizer Oncology Clinical Trial Information Service		Ph: 1-877-369-9753
		Email: PfizerCancerTrials@emergingmed.com

Pfizer CT.gov Call Center

Ph: 1-800-718-1021

Trial Sites

U.S.A.

Missouri

Creve Coeur

Pfizer Investigational Site

St. Louis

Pfizer Investigational Site

St. Peters

Pfizer Investigational Site

New York

New York

Pfizer Investigational Site

Virginia

Norfolk

Pfizer Investigational Site

Argentina

Rosario

Pfizer Investigational Site

Australia

Perth

Pfizer Investigational Site

South Australia

Adelaide

Pfizer Investigational Site

Victoria

Heidelberg

Pfizer Investigational Site

Belgium

Bruxelles

Pfizer Investigational Site

Canada

Nova Scotia

Halifax

Pfizer Investigational Site

Colombia

Medellin

Pfizer Investigational Site

France

CLICHY CEDEX

Pfizer Investigational Site

LYON CEDEX 03

Pfizer Investigational Site

MARSEILLE CEDEX 5

Pfizer Investigational Site

PARIS

Pfizer Investigational Site

RENNES CEDEX

Pfizer Investigational Site

Rennes Cedex

Pfizer Investigational Site

Germany

Berlin

Pfizer Investigational Site

Kiel

Pfizer Investigational Site

Muenchen

Pfizer Investigational Site

Hong Kong

Hong Kong

Pfizer Investigational Site

Tuen Mun, New Territories

Pfizer Investigational Site

Wan Chai,

Pfizer Investigational Site

Mexico

Chihuahua

Pfizer Investigational Site

Monterrey

Pfizer Investigational Site

Republic of Korea

Daegu

Pfizer Investigational Site

Incheon

Pfizer Investigational Site

Seoul

Pfizer Investigational Site

Republic of Singapore

Singapore

Pfizer Investigational Site

Spain

BARCELONA

Pfizer Investigational Site

MADRID

Pfizer Investigational Site

PALMA DE MALLORCA

Pfizer Investigational Site

SABADELL

Pfizer Investigational Site

Taiwan, Province of China

Changhua

Pfizer Investigational Site

Kaohsiung

Pfizer Investigational Site

Tainan

Pfizer Investigational Site

Taipei

Pfizer Investigational Site

United Kingdom

Cardiff

Pfizer Investigational Site

Nottingham

Pfizer Investigational Site

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00428220
Information obtained from ClinicalTrials.gov on September 25, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.